{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T00:36:39Z","timestamp":1714610199575},"reference-count":16,"publisher":"ALUNA","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Wiad Lek"],"published-print":{"date-parts":[[2024,3]]},"abstract":"<jats:p>Aim: To analyze the data and evaluate the prevalence of ocular lesions in patients with moderate ulcerative colitis.\nMaterials and Methods: We observed 112 patients aged 18-75 years old with clinically, endoscopically and histologically confirmed moderate ulcerative colitis which lasted at least 6 months. An ophthalmologic exam was performed to determine the presence of ocular symptoms.\nResults: Of the 112 patients with moderate ulcerative colitis, 21 (18,75%) had the following ocular lesions: episcleritis - 7 patients (6,25%), keratopathy \u2013 5 patients (4,46%), uveitis - 5 patients (4,46%), cataract - 2 (1,78%) and scleritis - 2 (1.78%).\nConclusions: Because ocular symptoms in patients with UC are often nonspecific, it may be beneficial to perform ophthalmologic examinations as a routine follow-up component of in such patients.<\/jats:p>","DOI":"10.36740\/wlek202403111","type":"journal-article","created":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T17:01:45Z","timestamp":1714582905000},"page":"445-449","source":"Crossref","is-referenced-by-count":0,"title":["Ocular lesions in patients with ulcerative colitis"],"prefix":"10.36740","volume":"77","author":[{"given":"Antonina V.","family":"Varvarynets","sequence":"first","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerii D.","family":"Beliayev","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mykhailo M.","family":"Hechko","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Artur V.","family":"Kurakh","sequence":"additional","affiliation":[{"name":"UZHHOROD NATIONAL UNIVERSITY, UZHHOROD, UKRAINE"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"22436","published-online":{"date-parts":[[2024]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"1. Vavricka SR, Schoepfer A, Scharl M et al. Extraintestinal manifestations of inflammatory bowel diseas. Inflamm Bowel Dis. 2015;21(8):1982\u20131992. doi: 10.1097\/MIB.0000000000000392.","DOI":"10.1097\/mib.0000000000000392"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Ungaro R, Mehandru S, Allen PB et al. Ulcerative colitis. Lancet. 2017;389:1756\u20131770. doi: 10.1016\/S0140-6736(16)32126-2.","DOI":"10.1016\/s0140-6736(16)32126-2"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"3. Algaba A, Guerra I, Ricart E et al. Extraintestinal Manifestations in Patients with Inflammatory Bowel Disease: Study Based on the ENEIDA Registry. Dig. Dis. Sci. 2021;66(6):2014\u20132023. doi: 10.1007\/s10620-020-06424-x.","DOI":"10.1007\/s10620-020-06424-x"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Mittal R, Patel S, Galor A. Alternative therapies for dry eye disease. Curr Opin Ophthalmol. 2021;32(4):348-361. doi: 10.1097\/ICU.0000000000000768.","DOI":"10.1097\/icu.0000000000000768"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Generali E, Cantarini L, Selmi C. Ocular involvement in systemic autoimmune diseases. Clin Rev Allergy Immunol. 2015;49(3):263-70. doi: 10.1007\/s12016-015-8518-3.","DOI":"10.1007\/s12016-015-8518-3"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Lee HJ , Song HJ, Jeong JH et al. Ophthalmologic manifestations in patients with inflammatory bowel disease. Intest Res. 2017;15(3):380-387. doi: 10.5217\/ir.2017.15.3.380.","DOI":"10.5217\/ir.2017.15.3.380"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Do\u011fan M , Ozcan S, Acarturk G et al. Conjunctival impression cytology and tear-film changes in patients with inflammatory bowel disease. Eye Contact Lens. 2018;44(2):S420-S425. doi: 10.1097\/ICL.0000000000000537.","DOI":"10.1097\/icl.0000000000000537"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Mady R, Grover W, Butrus S. Ocular Complications of Inflammatory Bowel Disease. ScientificWorldJournal. 2015:2015:438402. doi:10.1155\/2015\/438402.","DOI":"10.1155\/2015\/438402"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Troncoso LL, Biancardi AL, de Moraes HV Jr, Zaltman C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review. World J Gastroenterol. 2017;23(32):5836-5848. doi: 10.3748\/wjg.v23.i32.5836.","DOI":"10.3748\/wjg.v23.i32.5836"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Shah J, Shah A, Hassman L, Gutierrez A. Ocular Manifestations of Inflammatory Bowel Disease. Inflamm Bowel Dis. 2021;27(11):1832- 1838. doi: 10.1093\/ibd\/izaa359.","DOI":"10.1093\/ibd\/izaa359"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Sharma SM, Damato E, Hinchcliffe AE et al. Long-term efficacy and tolerability of TNFalpha inhibitors in the treatment of noninfectious ocular inflammation: an 8-year prospective surveillance study. Br J Ophthalmol. 2021;105(9):1256-1262. doi: 10.1136\/ bjophthalmol-2018-312767.","DOI":"10.1136\/bjophthalmol-2018-312767"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Mercier AE, Ribeiro E, Korobelnik JF et al. Efficacy of anti-TNF-\u03b1 therapy for the treatment of non-infectious uveitis: a retrospective study of 21 patients. Ocul Immunol Inflamm. 2018;26(3):477-484. doi: 10.1080\/09273948.2016.1236968.","DOI":"10.1080\/09273948.2016.1236968"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Sandborn WJ, Su C, Sands BE et al. Tofacitinib as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2017;376(18):1723- 1736. doi: 10.1056\/NEJMoa1606910.","DOI":"10.1056\/nejmoa1606910"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"14. Paley MA, Karacal H, RaoPK et al. Tofacitinib for refractory uveitis and scleritis. Am J Ophthalmol Case Rep. 2018;13:53-55. doi: 10.1016\/j.ajoc.2018.12.001.","DOI":"10.1016\/j.ajoc.2018.12.001"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Yilmaz S, Aydemir E, Maden A, Unsal B. The prevalence of ocular involvement in patients with inflammatory bowel disease. Int J Colorectal Dis. 2007;22(9):1027-30. doi: 10.1007\/s00384-007-0275-1.","DOI":"10.1007\/s00384-007-0275-1"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Cuny A, Guillo L, Baumann C et al. Ocular Manifestations in Patients with Inflammatory Bowel Disease in the Biologics Era. J Clin Med. 2022;11(15):4538. doi: 10.3390\/jcm11154538.","DOI":"10.3390\/jcm11154538"}],"container-title":["Wiadomo\u015bci Lekarskie"],"original-title":[],"language":"en","deposited":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T17:09:08Z","timestamp":1714583348000},"score":1,"resource":{"primary":{"URL":"https:\/\/wiadlek.pl\/wp-content\/uploads\/archive\/2024\/WiadLek2024i3.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":16,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024]]},"published-print":{"date-parts":[[2024,3]]}},"URL":"https:\/\/doi.org\/10.36740\/wlek202403111","archive":["Internet Archive"],"relation":{},"ISSN":["0043-5147"],"issn-type":[{"value":"0043-5147","type":"print"}],"subject":[],"published":{"date-parts":[[2024]]}}}